Skip to main content
Fig. 8 | BMC Infectious Diseases

Fig. 8

From: Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis

Fig. 8

Survival profiles of vaccinated mice against lethal toxoplasmosis. Eight mice from all four groups were challenged with 1 × 105T. gondii Ankara strain tachyzoites nine weeks after the prime vaccination. T. gondii tachyzoites were administered to mice vaccinated with hexavalent recombinant protein mixture (+) Montanide ISA 50 V (■), and the control groups hexavalent recombinant protein mixture (×), Montanide ISA 50 V (), and PBS (♦)

Back to article page